AI assistant
Avidity Biosciences, Inc. — Director's Dealing 2025
Jun 13, 2025
30894_dirs_2025-06-12_12981105-3e98-4bcc-8647-0cbb84968b0b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-06-10
Reporting Person: Kaye Edward M. MD (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-10 | Common Stock | A | 6692 | — | Acquired | 6692 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-10 | Stock Option (Right to Buy) | $33.62 | A | 10034 | Acquired | 2035-06-09 | Common Stock (10034) | Direct |
Footnotes
F1: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date.
F2: This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date.